In an exciting development in the field of liver health, pre-clinical data from McMaster University highlights a new drug candidate capable of reversing metabolic liver disease and fibrosis. This groundbreaking research addresses a significant medical challenge, as liver fibrosis often progresses to cirrhosis, which can be deadly. The drug operates by targeting specific pathways involved in the development of fibrosis, showing promising results in laboratory models. These findings could pave the way for novel therapeutic avenues, offering hope to millions affected by chronic liver diseases. Researchers are optimistic about the potential for human trials, aiming to transform the management of liver fibrosis and metabolic liver conditions. With liver disease rates rising globally, this breakthrough holds particular importance for the future of hepatology and chronic disease management.
healthsci.mcmaster.caNew data shows smarter solutions to change-of-mind returns as retailers crack down
August 3, 2026
In a bid to address the rising costs associated with change-of-mind returns, many retailers are implementing stricter policies. However, recent data suggests that a more